Dr. Spitalnik on Goals for the Hemanext® Blood Storage System in Hematologic Malignancies

Video

In Partnership With:

Steven L. Spitalnik, MD, discusses the goals for the Hemanext® blood storage system in patients with hematologic malignancies. 

Steven L. Spitalnik, MD, co-director, Laboratory of Transfusion Biology, professor, Pathology and Cell Biology, vice-chairman, Laboratory Medicine, Columbia University Medical Center, discusses the goals for the Hemanext® blood storage system in patients with hematologic malignancies. 

The goal of the Hemanext® blood storage system is to further the understanding of red blood cell storage biology and platelet transfusions, and hopefully produce a product that better serves patients, according to Spitalnik. Moreover, developing a better understanding of the dosing and activity of red blood cells may result in better outcomes for patients, Spitalnik adds.

Current data on this blood storage technology suggest that it enables more red cells to circulate for longer periods of time, Spitalnik explains. For patients who undergo chronic transfusions, this system could lead to fewer transfusions, and a better quality of life, Spitalnik concludes.

Related Videos
Vishal Patel, MD, FAAD, FACMS, associate professor, Dermatology, George Washington (GW) School of Medicine & Health Sciences
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP